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Objectives: Non–small cell lung cancer with mediastinal lymph node
involvement is a heterogeneous entity different from single mediastinal
lymph node metastasis to multiple nodes or extranodal disease. The
objective of this study was to identify the subpopulation of patients with
N2 disease who can benefit from surgical intervention.
Methods: We reviewed 219 consecutive patients with N2 non–small cell
lung cancer treated with a thoracotomy between November 1980 and June
2002 and retrospectively analyzed 154 of those who had p-stage IIIA
disease and underwent a complete resection. Age, sex, side (right or left),
histology, location (upper or middle-lower lobe), tumor size, c-N factor,
and N2 level (single or multiple) were used as prognostic variables.
Results: The 3- and 5-year survivals were 45.3% and 28.1%, respectively,
in patients with p-stage IIIA (N2) disease. Survival for those with single
N2 non–small cell lung cancer was significantly better than in those with
multiple N2 disease (P .0001), and patients with a tumor in the upper lobe showed
a significantly longer survival than those with middle-lower lobe involvement (P 
.0467). The 3- and 5-year survivals for patients with single N2 disease with a
primary tumor in the upper lobe were 74.9% and 53.5%, respectively. A multivar-
iate analysis with Cox regression identified 5 predictors of better prognosis: younger
age, squamous cell carcinoma as determined by histology, primary tumor location
in the upper lobe, c-N0 status, and a single station of mediastinal node metastasis.
Conclusion: Our results suggest that of the heterogeneity of N2 diseases, patients
with single N2 disease with non–small cell lung cancer in the upper lobe are good
candidates for pulmonary resection.
Non–small cell lung cancer (NSCLC) with ipsilateral mediastinallymph node metastasis is generally considered to be a locallyadvanced disease resulting in a poor outcome, although thesepatients can be divided into heterogeneous subpopulations, suchas those with bulky extranodal metastases and those with eithermultiple or single N2 involvement. Among these patients, a
proportion of patients with N2 disease, including surgically discovered patients with
positive nodes, have been treated with pulmonary resection. The overall 5-year
survival in patients with N2 disease who underwent a curative resection has been
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reported to range from 19% to 36%; however, most retro-
spective studies of surgical results of treated patients with
N2 NSCLC were highly selective.1 Furthermore, several
prognostic factors have recently been defined by historical
studies, which have shown that complete resection, single
mediastinal node metastasis, c-N0-1, low p-T factor, and
small tumor size are predictors of better prognosis in pa-
tients with N2 NSCLC.2-5 However, the type of patients
with N2 NSCLC who can benefit most from a thoracotomy
has not been clarified. We retrospectively studied patients
with N2 NSCLC treated at our institute by analyzing prog-
nostic factors to identify subpopulations with good opera-
tive indications.
Patients and Methods
Patients
The records of all 219 patients with NSCLC who underwent a
thoracotomy and were confirmed to have positive mediastinal
nodes between November 1980 and June 2002 at Toneyama Na-
tional Hospital, Osaka, Japan, were reviewed. Three patients died
of postoperative complications and were excluded from the present
study. In principle, we considered patients with single N2 disease
to be resectable and those with extranodal or bulky mediastinal
node involvement or multiple N2 disease to be inoperable. Thus
163 patients underwent a complete resection (154 for p-stage IIIA,
8 for p-stage IIIB, and 1 for p-stage IV), and an incomplete
resection and exploratory thoracotomy were performed in 28 pa-
tients for each.
In the present study we focused on the 154 patients with p-stage
IIIA (N2) disease treated with a complete resection (Table 1).
Follow-up was complete in 131 patients, and the median time for
follow-up of all patients was 111.2 months. The mediastinal lymph
node was pathologically confirmed to be metastatic in all patients
who underwent a pulmonary resection. Preoperative diagnosis was
performed by using chest radiography and computed tomographic
(CT) imaging, as well as fiberoptic bronchoscopy for pulmonary
nodules. Mediastinal nodes larger than 1 cm in the short axis were
defined as clinical N2 disease. A mediastinoscopy was carried out
in selected patients because of protocol setting or in some with
suspected c-N2 disease before induction therapy, although not
routinely. Brain CT or magnetic resonance imaging results, as well
as those from upper abdominal CT and bone scintigraphy exami-
nations, were used to detect distant metastases. Postoperative
staging was performed according to the 1997 TNM classification.6
All dissected hilar and mediastinal lymph nodes were pathologi-
cally examined and classified according to anatomic location by
using Naruke’s numbering system.7 Complete resection was de-
fined as that without a macroscopic residual lesion and with
microscopic free margins around the tumor site. Patients with
pleural dissemination or malignant pleural effusion were defined
as having an incomplete resection, even if there was no macro-
scopic residual lesion after the pulmonary resection. Induction and
adjuvant therapy were performed in 22 and 46 patients, respec-
tively. Eighty-six patients were treated with surgical intervention
alone. All patients treated with induction therapy had been given a
diagnosis of c-N2 disease on the basis of CT scanning or medias-
tinoscopy. As for lymph node dissection, in patients with a tumor
in the right upper-middle lobe, the superior mediastinal, paratra-
cheal, pretracheal, tracheobronchial, and subcarinal nodes were
removed. In those with a tumor in the left upper lobe, the tracheo-
bronchial, subaortic, para-aortic, and subcarinal nodes were re-
moved. In addition to these nodes, paraesophageal and pulmonary
ligament nodes were dissected in patients with tumors in both
lower lobes. The pretracheal node in patients with a left-side tumor
and the anterior and posterior mediastinal nodes were optional.
Patients were evaluated on the basis of age, sex, side (right or
left), histology, tumor location (upper lobe or middle-lower lobe),
largest diameter of the tumor, c-N factor, and metastatic medias-
tinal lymph node level (single or multiple) to determine prognostic
factors.
Statistical Analysis
Overall survival denotes the period from the date of initial treat-
ment. The probability of survival was calculated by using the
Kaplan-Meier method.8 The prognostic influence of variables on
survival was analyzed by using a log-rank test and a Cox propor-
tional hazards model.9
TABLE 1. Characteristics of 154 patients with p-stage IIIA
(N2) NSCLC (from our patient database: November 1980-
June 2002)
Age (y) 38–80 (median, 62)
Sex
Female 55
Male 99
c-N factor
c-N0 71
c-N1 20
c-N2 60
c-N3 3
N2 level
Single 75
Multiple 79
Histology
Ad 101
Sq 41
La 11
Ad-Sq 1
Side
Right 99
Left 55
Treatment
Surgical intervention alone 86
Surgical intervention  CT 39
Surgical intervention  RT 11
Surgical intervention  CRT 18
(Induction therapy, 22)
Mode
Pneumonectomy 25
Lobectomy 126
Partial resection 3
Ad, Adenocarcinoma; Sq, squamous cell carcinoma; La, large cell carci-
noma; Ad-Sq, adenosquamous cell carcinoma; CT, chemotherapy; RT,
radiation therapy; CRT, chemoradiation therapy.
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Results
The 3- and 5-year survivals for patients with p-stage IIIA
(N2) disease who underwent a complete resection were
45.3% and 28.1%, respectively (Figure 1). The 5-year sur-
vivals for patients with c-N0, c-N1, and c-N2-3 disease
were 45.5%, 26.5%, and 12.0%, respectively. The survival
of patients with c-N0 disease was significantly better than
that of patients with c-N2-3 disease (P  .0001). No sig-
nificant difference was found between the c-N0 and c-N1
groups (P  .2249). Median survival time (MST) was 49.5
months for the c-N0 group, 37.7 months for the c-N1 group,
and 17.9 months for the c-N2-3 group. Thus preoperative
c-N factor, determined with a chest CT scan, was able to
predict prognosis because surgically discovered patients
with N2 disease had a better outcome than those given a
preoperative diagnosis of c-N2 disease.
We also assessed survival by histologic type. The 5-year
survival and MST were 39.6% and 46 months, respectively,
for patients with squamous cell carcinoma; 23.9% and 30.6
months, respectively, for patients with adenocarcinoma; and
18.2% and 15.4 months, respectively, for patients with large
cell carcinoma. We found a significant difference between
patients with squamous cell carcinoma and those with large
cell carcinoma (P  .0200). Furthermore, the survival for
patients with squamous cell carcinoma showed a tendency
to be better than that for patients with adenocarcinoma,
although the difference was not significant (P  .0826).
In the present study a single metastasis in the mediastinal
node was retrospectively found in 75 patients, and multiple
metastases were found in 79 patients. The 5-year survival
and MST for patients with single N2 disease were 42.7%
and 48.5 months, respectively, which were both signifi-
cantly better than those seen in the multiple N2 group,
which had a 5-year survival of 15.5% and MST of 23.6
months (Figure 2). The outcome for patients with multiple
N2 disease who underwent a complete resection was poor,
although it was better than that for patients treated with an
incomplete resection, who had an MST of 14.2, or those
with exploratory thoracotomy, who had an MST of 13.9
months.
We speculated that patients with single N2 disease with
a primary lesion in the upper lobe tended to survive longer
than patients with other types of N2 disease, and therefore
we studied survival difference on the basis of tumor loca-
tion. The 5-year survival and MST for patients with a tumor
in the upper lobe were 34.6% and 37.7 months, respectively,
which were significantly better than those for patients with
a lesion in the middle-lower lobe (Figure 3).
When analyzed according to both N2 level and tumor
location (upper or middle-lower lobe), the 3- and 5-year
survivals were 74.9% and 53.5%, respectively, and MST
was 124 months in patients with single N2 disease and an
upper lobe primary tumor, which were significantly better
than the results for patients with multiple N2 disease (Figure
4). Metastatic mediastinal lymph nodes in single N2
NSCLC are listed in Table 2 according to tumor location.
Lesions in the upper lobe were mainly metastasized to the
upper mediastinal nodes, and those in the middle-lower lobe
were mainly metastasized to the subcarinal nodes. We fur-
ther analyzed patients with single N2 disease with an upper
lobe lesion to investigate outcome by side. The 5-year
survival was 70.0% in patients with a left upper lobe lesion
involving a subaortic or para-aortic lymph node (n  10)
and 55.4% in patients with a right upper lobe lesion involv-
ing a superior mediastinal, paratracheal, pretracheal, or tra-
cheobronchial node (n  22, P  .5095). Although the
number of patients was small, the 5-year survival of those
with a left upper lobe lesion was extremely good.
A univariate analysis using the variables listed in Table
3 showed that histology (large cell carcinoma/squamous cell
carcinoma), location (middle-lower lobe/upper lobe), tumor
diameter, c-N factor (c-N2-3/c-N0), and N2 level (multiple/
single) were significant prognostic factors. Patient age also
Figure 1. Overall survival for 154 patients with p-stage IIIA (N2)
NSCLC who underwent a complete resection.
Figure 2. Probability of survival for patients with stage IIIA (N2)
NSCLC who underwent a complete resection according to N2
level. Survival for those with single N2 disease was significantly
better than for those with multiple N2 disease.
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showed a prognostic factor trend, although it was not sig-
nificant, whereas sex and tumor side did not have a prog-
nostic effect. Using these variables, we also performed a
multivariate analysis (Table 4). We found that age, histol-
ogy (both adenocarcinoma and large cell carcinoma/squa-
mous cell carcinoma), location (middle-lower lobe/upper
lobe), c-N factor (c-N2-3/c-N0), and N2 level (multiple/
single) were independent prognostic predictors.
Discussion
Surgical indication for a patient with N2 NSCLC is gener-
ally marginal because of local advancement and poor prog-
nosis; however, it has recently been reported that a propor-
tion of patients with N2 NSCLC might have a good chance
of survival after a pulmonary resection.2,4,5,10 Although
several potential prognostic factors have been tested, it is
still unclear which of these patients might benefit most from
surgical intervention. In the present study we retrospec-
tively analyzed patients with p-stage IIIA (N2) disease in
Figure 3. Probability of survival for patients with stage IIIA (N2)
NSCLC who underwent a complete resection according to pri-
mary tumor location. Two patients with a tumor in the left main
bronchus were excluded from these results. Patients with a
tumor in the upper lobe showed a significantly longer survival
compared with that in those with a tumor in the middle-lower
lobe.
Figure 4. Probability of survival for patients with stage IIIA (N2)
NSCLC who underwent a complete resection according to both
N2 level and tumor location. Two patients with a tumor in the left
main bronchus were excluded from these results. The survival of
patients with single N2 disease and upper lobe primary involve-
ment was significantly better compared with that of those with
multiple N2 disease and upper lobe primary involvement (P 
.0010) or those with multiple N2 disease and middle-lower lobe
primary involvement (P < .0001) and also tended to be better than
survival in patients with single N2 disease and middle-lower lobe
primary involvement (P  .0900).
TABLE 2. Prevalence of mediastinal positive lymph nodes
according to location of the primary lesion in patients with
single N2 p-stage IIIA NSCLC
Station no. RUL LUL RMLL LLL
1 1 1
2 2
3 13 1 1 1
3a 3 1 2
3p 1 1
4 6 1 2
5 7 1
6 3
7 2 1 13 5
8 1 1 1
9 2
Station, Mediastinal lymph node station according to Naruke’s numbering
system7; RUL, right upper lobe; LUL, left upper lobe; RMLL, right middle-
lower lobe; LLL, left lower lobe.
TABLE 3. Potential prognostic factors in patients with p-
stage IIIA (N2) NSCLC by univariate analysis
Variables
Hazard
ratio 95% CL P value
Age 1.024 0.999-1.050 .0618
Sex (male/female) 1.198 0.790-1.817 .3958
Side (right/left) 1.055 0.700-1.590 .7975
Histology
Sq 1.000
Ad 1.531 0.951-2.464 .0794
La 2.517 1.201-5.273 .0145
Location (ML/U) 1.490 1.003-2.216 .0484
Tumor size 1.153 1.011-1.315 .0331
c-N
N0 1.000
N1 1.453 0.779-2.709 .2399
N2-3 2.807 1.812-4.348 .0001
N2 (multiple/single) 2.189 1.455-3.293 .0002
CL, Confidence limit; Sq, squamous cell carcinoma; Ad, adenocarcinoma;
La, large cell carcinoma; ML, middle-lower lobe; U, upper lobe.
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our institute to identify subpopulations suitable for pulmo-
nary resection, and our results indicated that patients with
single N2 involvement with NSCLC in the upper lobe
would be good candidates for a possible curative resection.
We expected that survival for patients with single N2
disease would be significantly better than that for those with
multiple N2 disease (Figure 2) because the latter is defini-
tively an advanced status, and other reports have shown a
significantly better survival in such patients with N2
NSCLC.2-5,11-17 Furthermore, Luzzi and associates18 noted
that patients with less than 50% lymph node infiltration,
which was calculated as the ratio of positive nodes to all
dissected mediastinal nodes, showed a significantly more
favorable outcome. We believe that those results are impor-
tant when considering surgical indications in patients with
N2 NSCLC because patients with single and multiple N2
disease are heterogeneous subpopulations that have very
different prognoses. The 5-year survival of 42.7% and MST
of 48.5 months for patients with single N2 NSCLC in the
present study suggest that patients with less advanced N2
NSCLC could be cured by, or at least benefit from, surgical
resection.
It was interesting to note differences in survival of pa-
tients with N2 NSCLC by location of the primary tumor
(upper vs middle-lower lobe, Figure 3). When analyzing
only patients with single N2 disease with a tumor in the
upper lobe, the 5-year survival was 53.5% (Figure 4), which
was somewhat surprising because it was similar or better
than that reported for N1 NSCLC.6,19 Because we found no
survival difference by location of the primary lesion in
patients with p-N0 or pN1 NSCLC in our institute (data not
shown), a better prognosis for patients with an upper lobe
lesion was an interesting characteristic of N2 NSCLC dis-
ease. Ichinose and colleagues5 pointed out the relationship
between primary tumor location and metastatic N2 station
(ie, there were frequent metastases from the right upper lobe
at no. 3, from the left upper lobe at no. 5, and from the right
middle-lower and left lower lobes at no. 7). In the present
study we also observed a similar tendency of prevalent
positive nodes (Table 2). Furthermore, the outcome of N2
NSCLC associated with upper mediastinal lymph node in-
volvement has been reported to be better compared with that
with lower mediastinal metastasis.10,11,20 Thus we suppose
that there is a relationship between upper mediastinal node
involvement and a tumor located in the upper lobe and,
furthermore, that this particular subpopulation could benefit
from complete resection. We also propose that a prethora-
cotomy evaluation by tumor location provides more infor-
mation to predict the prognosis of patients than that by site
of metastatic node.
Patients with c-N0 status showed significantly better
survival than those with c-N2-3 status (Tables 3 and 4). This
result has also been shown in other studies, and c-N diag-
nosis using chest CT scanning is an important reference
factor.2,4,10,15 However, it has been reported that lymph
node size detected on the basis of CT is not reliable for an
evaluation of metastasis.21 Therefore we propose that a
more accurate evaluation for mediastinal lymph nodes is
necessary. We recently adopted fiberscopic transbronchial
needle aspiration, mediastinoscopy, and/or exploratory tho-
racoscopy for preoperative evaluation of patients with c-N2
disease given a diagnosis on the basis of chest CT scanning.
Although fluorodeoxyglucose–positron emission tomogra-
phy might be useful in the evaluation of mediastinal nodes,
the accuracy is still less than that of mediastinoscopy.22,23
Thus we believe that accurate preoperative staging with
these examinations can contribute to the decision of surgical
indication and better prognosis for patients with less ad-
vanced N2 NSCLC.
Univariate and multivariate analyses showed that histo-
logic type was one of the prognostic factors in completely
resected stage IIIA (N2) NSCLC (Tables 3 and 4). Further-
more, the outcome of patients with squamous cell carci-
noma was significantly better than that of those with ade-
nocarcinoma or large cell carcinoma in the present study. A
better survival in patients with squamous cell carcinoma
compared with those with nonsquamous cell carcinoma was
previously mentioned by Vansteenkiste and colleagues15
and Goldstraw and associates16 with significant differences,
whereas Suzuki and coworkers,2 Martini and colleagues,10
and Nakanishi and associates20 found no significant results
by histologic type. In their studies Suzuki and coworkers2
and Nakanishi and associates20 compared adenocarcinoma
with other histologic findings, which were mainly squamous
cell carcinoma; however, they also included large cell car-
cinoma and adenosquamous cell carcinoma, which are gen-
erally considered to be more malignant in patients with
TABLE 4. Potential prognostic factors in patients with p-
stage IIIA (N2) NSCLC by multivariate analysis
Variables
Hazard
ratio 95% CL P value
Age 1.034 1.009-1.060 .0066
Sex (male/female) 1.423 0.901-2.247 .1306
Side (right/left) 1.015 0.657-1.568 .9469
Histology
Sq 1.000
Ad 3.048 1.710-5.432 .0002
La 7.328 3.083-17.416 .0001
Location (ML/U) 1.578 1.030-2.419 .0362
Tumor size 1.111 0.955-1.293 .1713
c-N
N0 1.000
N1 1.563 0.764-3.194 .2210
N2-3 3.028 1.842-4.978 .0001
N2 (multiple/single) 1.883 1.208-2.936 .0052
See abbreviations in Table 3.
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NSCLC.24 In contrast to our report, Martini and col-
leagues10 did not perform a multivariate analysis. From
their and our results, we considered that squamous cell
carcinoma histology is a better prognostic predictor in ad-
dition to single N2 status and tumor location in the upper
lobe in patients with p-stage IIIA (N2) NSCLC.
A portion of the patients (22/154) in the present study
were treated with induction therapy, and their outcome also
depended on the status of persistent N2.25-27 Regarding the
level of mediastinal node metastasis, Sawabata and cowork-
ers28 recently clarified that the chance of 5-year survival
was 54% for single-level and 11% for multiple-level per-
sistent N2 disease after induction therapy. These findings
are similar to the results in the present study.
The Toronto group reported that patients with a lesion in
the right upper lobe frequently had upper mediastinal node
involvement, suggesting a direct lymphatic drainage mech-
anism from the primary tumor to the right paratracheal or
tracheobronchial lymph nodes.29 Later, they also reported
that good prognosis could be predicted after complete re-
section in patients with a primary tumor in the left upper
lobe associated with only subaortic node involvement.30
Our results are compatible with the results of those reports,
and we additionally clarified 2 new findings in the present
study, which were that single N2 involvement, upper lobe
tumor, and histology of squamous cell carcinoma were
better independent prognostic predictors by means of mul-
tivariate analysis in patients with N2 NSCLC, and the
5-year survival of patients with single N2 NSCLC with an
upper lobe tumor was similar to that of patients with N1
NSCLC and better than results of previous reports.
In summary, younger age, squamous cell carcinoma his-
tology, tumor in the upper lobe, single N2 NSCLC, and
c-N0 status on a chest CT scan were better independent
prognostic predictors. Among the heterogeneous entities,
we considered that a patient with a single N2 NSCLC in the
upper lobe is the best candidate for pulmonary resection.
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